Letrozole API

Name	Letrozole
Chinese name	来曲唑
Cas Number	112809-51-5
Source	India/Taiwan
Qualifications	USDMF/CEP/-/-/-

The original manufacturer is Novartis Pharma Schweiz AG, which was first approved for marketing in the United States in 1997. Letrozole can effectively inhibit the conversion of androgens to estrogen and is especially suitable for postmenopausal breast cancer patients. Because of its high selectivity, it does not affect glucocorticoids, mineralocorticoids and thyroid function. Large-dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a higher therapeutic index. Various studies have shown that letrozole is not potentially toxic to the system and target organs of the whole body, and has the characteristics of good tolerance and strong pharmacological effects. Compared with other aromatase inhibitors and anti-estrogen drugs, letrozole has a stronger anti-tumor effect.

Hot Tags: letrozole api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Apremilast API, Solinasine Succinate API, Pleasant API, Lifitegrast API, Adapalene API, Cinacalcet Hydrochloride API

• Previous: Bosentan API
• Next: Fondaparinux API